Proponents of precision medicine cite the growing numbers of successful precision cancer drugs. The examples of Herceptin (trastuzumab), Gleevec (imatinib mesylate), Xalkori (crizotinib), and Zelboraf (vemurafenib) come to mind. Skeptics, on the other hand, focus on the … Read more
New research has shown that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.
BRAF inhibitors block the activity of mutated BRAF gene. They are currently … Read more
Platinum/taxane combinations are the most effective regimens for treatment of epithelial ovarian cancer. Response varies between patients, but because the molecular basis for resistance is not defined, patients receive so-called one size fits all therapy. In contrast, elucidation of the … Read more
While precision medicine has been a modern go-to approach by physicians in various malignancies, it is demonstrating a particular benefit in ovarian cancer, especially using the method for clinical trial enrollment and in determining whether patients are eligible to receive … Read more
By: Laura L. Holman, MD, MS
We’ve come a long way in treating ovarian cancer. This treatment has historically consisted of debulking surgery for nearly every patient, but it is evolving to become more informed and precise. Diagnostic laparoscopy, for … Read more
By: Hillary Theakston, Executive Director of The Clearity Foundation
In May, for the first time, the U.S. Food and Drug Administration approved a cancer drug for patients whose tumors are defined by a specific genetic feature (biomarker), rather than by … Read more
Medical science is more advanced than at any point in history. Yet the health care system — medical science applied to actual patients — still leaves many people without the best and latest treatments.
For example, new knowledge about health … Read more
The University of California, San Francisco announced last week that the California Initiative to Advance Precision Medicine (CIAPM) will provide $7.2 million in new funding to support to new precision medicine research projects.
The CIAPM was established in 2015 with … Read more
By: Annette McElhiney
Nearly everyone has heard the term Precision Medicine. However most of us have only a shallow understanding of what precision medicine means. To fully understand, go to the government web site and read the President’s initiative in … Read more
By: Cory Bentley, PhD
The Society for Gynecological Oncology (SGO) Meeting this March in San Diego brought together physicians and scientists from all over the world to share the latest research, treatments, and thinking in gynecological cancers including ovarian. Clearity … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
